Clinical trials: Chronic Hepatitis, B Virus
Liver Cirrhosis, Chronic Hepatitis B
Safety and Efficacy of Telbivudine on Liver Cirrhosis in Patients With Chronic Hepatitis B (CHB)
Antiviral treatment on Chronic Hepatitis B (CHB) patients with liver cirrhosis is compulsory and effective. Telbivudine, which is superior to lamivudine in the treatment of CHB,is considered to be appropriate for the antiviral…
- Trial name
- NCT01380951
- Testing
- telbivudine
- Where
- China
- Volunteers
- 120 people
- Sponsor
- The Fifth People's Hospital of Suzhou
HBV/HCV Co-infection
A Pilot Study To Evaluate the Efficacy of Response Guided Therapy of Peginterferon Alfa Plus Ribavirin in the Treatment of Patients With HCV/HBV Co-Infection
This is an open label, randomized-controlled, comparative trial. HBV and HCV dually infected patients with negative hepatitis B e antigen (HBeAg) were enrolled in the study.
- Trial name
- NCT02339337
- Testing
- Abbreviation of treatment duration
- Volunteers
- 203 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Chronic Hepatitis B Infection
Cohort Study of Clinical Outcomes in Chronic HBV Infection Patients With Low HBsAg Under Unplanned Intervention
All chronic hepatitis B (CHB) patients were diagnosed and treated in the liver disease department of the Hepatology Center of Beijing Ditan Hospital affiliated to Capital Medical University and those who received antiviral…
- Trial name
- NCT04030039
- Testing
- Interferon, nucleoside analogues
- Where
- China
- Volunteers
- 420 people
- Sponsor
- Beijing Ditan Hospital
Compensated Chronic Hepatitis B
Efficacy of Telbivudine in Blacks/African Americans and Hispanics/Latinos With Compensated Chronic Hepatitis B During 52 Weeks
The purpose of this study is to investigate the efficacy of telbivudine in Blacks/African Americans and Hispanics/Latinos with compensated chronic hepatitis B during 52 weeks of treatment
- Trial name
- NCT00862706
- Testing
- Telbivudine/LDT600A
- Where
- 6 sites in United States, Puerto Rico
- Sponsor
- Novartis Pharmaceuticals
Chronic Hepatitis B
A Study of ABI-H2158 in Healthy Volunteers and Patients With Chronic Hepatitis B
This three-part, Phase 1 protocol will be the first clinical study of ABI-H2158. Parts 1 and 2 will be a Phase 1a, dose-ranging assessment of ABI-H2158 in healthy adult volunteers.
- Trial name
- NCT03714152
- Testing
- ABI-H2158
- Where
- 14 sites in United States, Australia and 5 more
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Assembly Biosciences
Hepatitis B, Chronic
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Chronic Hepatitis B.
This single arm study will assess the efficacy and safety of PEGASYS in patients with chronic hepatitis B who are either treatment-naive, or who have failed lamivudine- or interferon-treatment in the past.
- Trial name
- NCT00487747
- Testing
- peginterferon alfa-2a [Pegasys]
- Where
- 23 sites in Russia
- Volunteers
- 18 people
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis B
A Study With Clevudine Monotherapy or Adefovir and Clevudine Combination in Patients With Chronic Hepatitis B
An open study to Evaluate the Efficacy, Safety and Sustained effect of Clevudine monotherapy or Adefovir and Clevudine combination in proportion to Roadmap concept in Patients with chronic hepatitis B.
- Trial name
- NCT01264133
- Testing
- Clevudine, Adefovir
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Bukwang Pharmaceutical
Chronic Hepatitis B
The Treatment of PD-1 Antibody Combined With Peg-IFNα in NAs-suppressed CHB Patients
This is a prospective, open-labled, randomized controlled study to assess efficacy and safety of treatment with Sintilimab (PD-1 antibody) combined Peg-IFNα-2b in CHB patients on stable NAs treatment.
- Trial name
- NCT06357806
- Testing
- Sintilimab, Peg-IFNα-2b, NAs
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Beijing 302 Hospital
Chronic Hepatitis B
Switching Therapy From Lamivudine to Telbivudine Versus Continued Lamivudine in Adults With Chronic Hepatitis B
This study is being conducted to compare the safety and effectiveness of switching treatment from lamivudine to telbivudine (LdT) against continued lamivudine treatment.
- Trial name
- NCT00132652
- Testing
- Lamivudine, Telbivudine
- Where
- 14 sites in United States, Australia and 9 more
- Volunteers
- 240 people
- Sponsor
- Novartis
Hepatitis B, Cirrhosis
A Comparison of the Drug Telbivudine (LdT) and Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis.
This trial is being done to see if the investigational drug, LdT (Telbivudine), is safe and effective in the treatment of hepatitis B infection.
- Trial name
- NCT00275652
- Testing
- LdT (Telbivudine) and lamivudine
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Mayo Clinic
Chronic Hepatitis b
Cross Sectional Survey on the Burden and Impacts of Chronic Hepatitis B in the Rural Area of Niakhar, Senegal
This study aims at estimating the prevalence of chronic hepatitis B virus (HBV) infection in rural Senegal (area of Niakhar) and at evaluating the associated burden in terms of both health-related and socio-economic consequences.
- Trial name
- AMBASS (NCT03215732)
- Testing
- HBV testing with dried blood spots (DBS) technique
- Where
- Senegal
- Volunteers
- 3,119 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
Hepatitis B, Chronic
Continuing Lamivudine Versus Switching to Entecavir in Patients Who Achieved Undetectable Hepatitis B Virus DNA
This is a randomized, open-labelled, prospective 96-week study comparing the antiviral efficacy and safety of switching to entecavir 0.5mg QD from lamivudine versus maintaining lamivudine 100mg QD treatment in CHB patients…
- Trial name
- NCT00637663
- Testing
- Entecavir, Lamivudine
- Where
- 2 sites in South Korea
- Volunteers
- 72 people
- Sponsor
- Pusan National University Hospital
Hepatitis B, Chronic
Linkage to Care and Treatment of Chronic HBV Patients
Chronic hepatitis B remains the leading cause of liver related mortality and morbidity globally and locally. Countries have been formulating initiatives to meet the WHO target of eliminating viral hepatitis by 2030.
- Trial name
- HBV (NCT06658678)
- Testing
- Receiving an educational intervention
- Where
- Hong Kong
- Volunteers
- 803 people
- Sponsor
- The University of Hong Kong
Chronic Hepatitis B
HBsAg Clearance in Inactive Chronic HBsAg Carriers After Interferon Treated
Hepatitis B surface antigen loss/seroconversion, considered to be the ideal outcome of chronic hepatitis B virus (HBV) infection, occurs spontaneously at a low rate in inactive carriers.
- Trial name
- NCT01471535
- Testing
- Pegylated interferon alfa-2a
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Beijing Ditan Hospital
Chronic HBV Infection
A Study of EDP-514 in Healthy Subjects (Part 1) and Patients With Chronic Hepatitis B Virus Infection (Part 2)
Part 1 is a randomized, double-blind, placebo-controlled study. It will assess the safety, tolerability, and pharmacokinetics of single and multiple orally administered doses of EDP-514 in healthy adult subjects.
- Trial name
- NCT04008004
- Testing
- EDP-514
- Where
- 15 sites in United States, Canada
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- Enanta Pharmaceuticals, Inc
Chronic Hepatitis B
Procurement of Blood Samples for a Biomedical Research Program on T Cell Functional Response to Chronic HBV Infection
The objective of the study is to procure blood (plasma, serum, RNA and PBMC samples) from approximately 40 chronic HBV for biomedical research program led by VGTI Florida.
- Trial name
- NCT02017587
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Vaccine and Gene Therapy Institute, Florida
Chronic Hepatitis B
Safety and Immunogenicity of a Naked DNA-based Vaccine Therapy in Patients With Chronic Hepatitis B
The purpose of this study was to investigate whether HBV-DNA vaccination is safe and could restore immune responses in patients with chronic hepatitis B non responder to available therapies.
- Trial name
- RBM99026 (NCT00988767)
- Testing
- DNA vaccine
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Chronic Renal Disease
Immunosenescence and Hepatitis B Virus (HBV) Vaccine Efficacy in Chronic Renal Disease Patient
The aim of this study is to investigate the role of immunosenescence in the HBV vaccination response in patients with renal insufficiency.
- Trial name
- IVVI (NCT02375711)
- Testing
- Blood sample
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Hepatitis B, Hepatitis B, Chronic
Cameroon Baptist Convention Health Board Chronic Hepatitis B Cohort Study
The natural history and response to therapy of chronic hepatitis B infection in West Africa are currently poorly understood. In this study, employees of the Cameroon Baptist Convention Health Board (CBCHB) and spouses who are…
- Trial name
- NCT02766933
- Where
- Cameroon
- Volunteers
- 207 people
- Sponsor
- Mayo Clinic
Hepatocellular Carcinoma, Hepatitis B
Discovering Urinary Protein Biomarkers for Hepatocellular Carcinoma in Chronic Hepatitis B Population
Chronic hepatitis B (CHB) can lead to hepatocellular carcinoma (HCC), imposing a significant health and economic burden globally.
- Trial name
- NCT06379334
- Testing
- Urine test
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.